Research and development expenses for the nine months decreased USD 1.5 million to USD 6.3 million, while general and administrative expenses rose USD 0.5 million to USD 6.9 million. The accumulatedDeficitstood at USD 114.8 million, compared with USD 101.4 million at the end of …
Restaurant revenue was USD 44.0 million, down 12.7%, reflecting a 9.2% decline in comparable restaurant sales and fewer restaurants. The company generated USD 4.7 million of consumer packaged goods revenue against none a year earlier, and retail distribution expanded to more than 2,000 doors.
Management citedGross Profitof USD 48 million, adjusted EBITDA of USD 44 million and cash flow from operations of USD 41 million, and said the company ended the quarter with USD 68 million of cash. The call described the results as significant beyond a single …
Management said the decline reflects continued pressure on its hardware businesses amid challenging market conditions. Net loss narrowed by USD 11.5 million to USD 3.4 million, against USD 14.9 million a year earlier. Non-IFRS net loss improved to USD 3.9 million from USD 6.7 …
Non-GAAP net income was USD 14.3 million, compared with USD 11.8 million a year earlier. Adjusted EBITDA reached USD 17.6 million, up from USD 15.6 million. For the first nine months, revenue was USD 349.4 million and adjusted EBITDA was USD 48.1 million.
Management said comparable sales reflected a 2.4% increase in traffic, partly offset by a 1.9% decrease in basket, and that traffic growth was driven by new customers.GAAPNet Incomewas USD 13.3 million, or USD 0.13 per diluted share, against USD 11.6 million, or USD 0.12.
Net loss was USD 48.1 million against USD 48.2 million a year earlier, and USD 77.8 million for the nine months against USD 123.1 million.Research and Developmentexpense was USD 18.8 million against USD 45.5 million, a decrease of USD 26.7 million that the filing …
The filing reportsNet Incomeof USD 0.1 million for the quarter and a net loss of USD 1.8 million for the nine months, which compares with a nine-month net loss of USD 10.1 million a year earlier and operating cash use of USD 6.9 million …
Management said revenue was in line with its guidance range and slightly lower than a year earlier because of a few large one-time transactions in the prior year period.
Management cited strength across key preclinical platforms, with double-digit momentum in products for organoids and fluidics and in newly introduced products. Revenue from its Chinese distribution partners grew 31%.